Lipid management in patients with diabetes mellitus

被引:18
作者
Brown, AS [1 ]
机构
[1] Midw Heart Dis Prevent Ctr, Naperville, IL USA
关键词
D O I
10.1016/j.amjcard.2005.07.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of diabetes mellitus has been increasing dramatically in recent decades. This trend closely follows the marked increase in the prevalence of obesity in the United States. As the proportion of the population with diabetes increases, the need for prevention and therapy to reduce cardiovascular events in these patients becomes critically important. Although plasma glucose control is important in reducing microvascular complications due to diabetes lipid management is essential in these patients to reduce the incidence of cardiovascular events. Adult patients with type 2 diabetes, in the absence of known coronary artery disease (CAD), have a similar 10-year risk for cardiac events as do patients without diabetes with established coronary disease. Recent clinical trials have highlighted the importance of aggressive plasma lipid lowering for both the primary and secondary prevention of atherosclerotic events in patients with diabetes. The likelihood of an ever-increasing diabetic patient population requires new systematic approaches to prevention as well as therapy for these patients and further development,of a team approach by the medical community to optimize care despite limited resources. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:26E / 32E
页数:7
相关论文
共 21 条
[1]  
Brown AS, 2002, AM J CARDIOL, V90, p44K
[2]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[3]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[4]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[5]  
Collins R, 2003, LANCET, V361, P2005
[6]  
*DIAB PREV PROGR R, 2002, NEW ENGL J MED, V346, P393, DOI [10.1056/NEJMoa012512, DOI 10.1056/NEJMOA012512]
[7]  
ESCHWEGE E, 1985, HORM METAB RES, V15, P41
[8]   CARDIOVASCULAR RISK-FACTORS IN CONFIRMED PREDIABETIC INDIVIDUALS - DOES THE CLOCK FOR CORONARY HEART-DISEASE START TICKING BEFORE THE ONSET OF CLINICAL DIABETES [J].
HAFFNER, SM ;
STERN, MP ;
HAZUDA, HP ;
MITCHELL, BD ;
PATTERSON, JK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (21) :2893-2898
[9]   LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL - The Strong Heart Study [J].
Howard, BV ;
Robbins, DC ;
Sievers, ML ;
Lee, ET ;
Rhoades, D ;
Devereux, RB ;
Cowan, LD ;
Gray, RS ;
Welty, TK ;
Go, OT ;
Howard, WJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (03) :830-835
[10]  
KENNY SJ, 1995, NIH PUBLICATION, P47